Nuevolution hires Takeda head as chief business officer
pharmafile | December 10, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Takeda, neuvolution
Small molecule lead discovery firm Nuevolution has poached Ton Berkien from Takeda to join the firm as a chief business officer.
Berkien will be leading Nuevolution’s commercial and business development efforts as an executive management member, and joins the company from Takeda/Nycomed where he was acting head of Corporate Development/M&A.
The firm’s chief executive Alex Gouliaev said: “The appointment of Ton has been made at a strategically important point in time for Nuevolution. We are very pleased that Ton has accepted to join us and look forward to benefit from his expertise in the commercialisation of Nuevolutions internal programmes.”
Berkien added: “I am very pleased to join Nuevolution at such an exciting time for the company. Together with the strong management team, I look forward to contribute to the company’s accelerated growth by driving the commercial efforts forward.”
Berkien served as senior director of corporate development at Takeda Pharmaceuticals, where he was responsible for several M&A transactions in the US, and Europe as well as in various emerging growth markets.
Prior to Takeda he held a similar position at Nycomed Pharmaceuticals. During 2003-2007 Berkien was director of Competitive Intelligence at Ferring Pharmaceuticals. Prior to that he held senior manager positions at PricewaterhouseCoopers, Rijnconsult, KPMG and Gilde Investment Management.
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
